GSK plc filings document the company's foreign private issuer disclosures for its American Depositary Shares and ordinary share capital. Recent Form 6-K reports cover product and collaboration announcements, share buyback activity, total voting rights, treasury shares, major holdings notifications and transactions by persons discharging managerial responsibilities.
The filing record also includes governance disclosures such as annual general meeting results, remuneration votes, board elections and shareholder resolutions. These reports connect GSK's biopharma operations with formal disclosures on capital structure, ownership, executive and director dealings, regulatory updates and shareholder governance.
GSK plc reported that on 18 November 2025 it transferred 22,000,000 ordinary shares held in treasury to the GlaxoSmithKline Employee Trust, a Jersey resident trust. These shares will be used to satisfy awards under the company’s Deferred Annual Bonus Plan, Performance Share Plan and Share Value Plan. The trustee paid £17.995 per share, funded by a loan from GlaxoSmithKline Services Unlimited.
After the transfer, GSK holds 234,819,844 ordinary shares in treasury and has 4,080,611,266 ordinary shares in issue, excluding treasury shares. The total number of voting rights is 4,080,611,266, and the percentage of voting rights attributable to treasury shares is 5.75%, which is relevant for shareholders’ disclosure calculations under UK rules.
GSK plc reports that, under its existing share buyback programme, it repurchased 185,000 ordinary shares on 18 November 2025 through BNP Paribas SA. The shares, with a nominal value of 31¼ pence each, were bought at prices between 1,771.00p and 1,803.00p, with a volume-weighted average price of 1,780.45p, and will be held as treasury shares.
Since 30 September 2025, GSK has purchased 9,355,000 ordinary shares under this programme. After this latest transaction, the company holds 234,819,844 shares in treasury and has 4,080,611,266 ordinary shares in issue excluding treasury shares. The total number of voting rights is 4,080,611,266, and the percentage of voting rights attributable to treasury shares is confirmed as 5.75 per cent.
GSK plc reported routine share dealings by senior personnel involving American Depositary Shares (ADSs). On 2025-11-14, Non-Executive Director Dr Hal Barron acquired approximately 2,732.837 notional ADSs in his GSK Executive Supplemental Savings Plan account and 69 ADSs in his GSK 401(k) plan account, both through the reinvestment of dividends at a price of $47.1800 per ADS. On the same date, James Ford, SVP and Group General Counsel, acquired 50.851 notional ADSs in his Executive Supplemental Savings Plan account, also via dividend reinvestment at $47.1800 per ADS. All transactions took place on the New York Stock Exchange.
GSK plc reports that on 17 November 2025 it repurchased 170,000 ordinary shares of 31¼ pence each through BNP Paribas SA under its existing buyback programme. The shares were bought at prices between 1,781.00p and 1,800.50p per share, with a volume-weighted average price of 1,789.39p, and will be held as treasury shares.
Since 30 September 2025, GSK has purchased 9,170,000 ordinary shares under this programme. After this transaction, it holds 256,634,844 shares in treasury and has 4,058,796,266 ordinary shares in issue, which is also the total number of voting rights. The percentage of voting rights represented by treasury shares is stated as 6.32%.
GSK plc reports that, acting through BNP Paribas SA, it repurchased 170,000 ordinary shares of 31¼ pence each on 14 November 2025 as part of its existing share buyback programme, at a volume-weighted average price of 1,788.23p per share, with prices ranging from 1,777.00p to 1,807.50p.
The repurchased shares will be held as treasury shares. Since 30 September 2025, the company has bought back a total of 9,000,000 ordinary shares under this programme.
After this transaction, GSK holds 256,464,844 shares in treasury and has 4,058,966,266 ordinary shares in issue, which is also the total number of voting rights. Treasury shares represent 6.32% of the voting rights attributable to ordinary shares.
GSK plc reported a routine share buyback transaction. Acting through BNP Paribas SA, the company purchased 167,000 ordinary shares on 13 November 2025 as part of its existing programme. Prices ranged from 1,794.50p to 1,817.50p with a volume‑weighted average price of 1,806.51p. The shares will be held as Treasury shares.
Since 30 September 2025, GSK has purchased 8,830,000 ordinary shares under the programme. After this purchase, GSK holds 256,294,844 shares in treasury and has 4,059,133,530 ordinary shares in issue (excluding treasury). Total voting rights are 4,059,133,530, and treasury-held voting rights represent 6.31%.
GSK plc reported routine insider share acquisitions by multiple senior executives under its Share Reward Plan. The transactions covered Ordinary Shares of 31 ¼ pence each (ISIN: GB00BN7SWP63) at £18.1420 per share on the London Stock Exchange.
Participants included CEO Emma Walmsley and CFO Julie Brown, each acquiring 14 Ordinary Shares (7 partnership and 7 matching). Other executives—James Ford, Sally Jackson, Regis Simard, Philip Thomson, and Victoria Whyte—also acquired 14 shares each on 2025-11-11. David Redfern acquired 12 shares (6 partnership and 6 matching). These are standard plan-related purchases disclosed via Form 6-K.
GSK plc reported a buyback transaction executed via BNP Paribas SA on 12 November 2025, purchasing 167,000 ordinary shares at a volume‑weighted average price of 1,813.49p (range 1,805.50p–1,827.00p). The shares will be held as treasury shares and form part of the company’s existing buyback programme under a non‑discretionary agreement announced on 30 September 2025.
Since 30 September 2025, GSK has purchased 8,663,000 shares. Following this transaction, GSK holds 256,127,844 shares in treasury and has 4,059,300,530 shares in issue (excluding treasury). The total number of voting rights is 4,059,300,530, and the percentage of voting rights attributable to treasury shares is 6.31%.
GSK plc filed a Form 6‑K reporting its UK block listing six‑monthly return for the period from 1 May 2025 to 31 October 2025, detailing movements under three employee share plans.
Under the GlaxoSmithKline plc 2017 Deferred Annual Bonus Plan, securities issued/allotted were 0, with a balance of unallotted securities of 115,518 at period end.
For the GlaxoSmithKline plc Share Save Plan 2012, securities issued/allotted were 134,547, leaving a balance of unallotted securities of 135,768 at period end.
For the GlaxoSmithKline plc Share Save Plan 2022, securities issued/allotted were 47,674, with a balance of unallotted securities of 904,117 at period end.
GSK plc reported share repurchases under its ongoing buyback. On 11 November 2025, the company bought 167,000 ordinary shares at prices between 1,791.50p and 1,825.00p, with a volume‑weighted average price of 1,807.35p. The shares will be held as treasury shares and the purchases were executed by BNP Paribas SA under a non‑discretionary agreement announced on 30 September 2025. Since that date, GSK has purchased 8,496,000 shares.
Following these transactions, GSK holds 255,960,844 shares in treasury and has 4,059,467,530 shares in issue (excluding treasury shares). The total number of voting rights is 4,059,467,530, and the percentage of voting rights attributable to treasury shares is 6.31%.